St. Jude Children’s Research Hospital study finds childhood cancer survivors are 14 percent more likely than peers to be obese; genetics may increase risk of treatment-related obesity for some survivors
Childhood cancer survivors – especially those whose treatment included brain irradiation or chemotherapy with glucocorticoids – are 14 percent more likely to be obese than their healthy peers. The St. Jude Children’s Research Hospital study appears today in the journal Cancer.
Of the 1,996 childhood cancer survivors in this study, 36.2 percent had a body mass index (BMI) of 30 kilograms per meters squared or more, which qualifies as obese. That was 14 percent greater than the expected prevalence based on federal health survey data of a comparison group of U.S. residents.
Among the strongest predictor of obesity in survivors was childhood obesity, which is also a strong predictor of adult obesity in the general public. Survivors who were obese when their pediatric cancer was discovered were almost five times more likely than other survivors to be obese when their BMI was calculated for this study.
Other obesity risk factors were age and childhood cancer treatment. Survivors who were ages 30 and older when their BMI was calculated were more likely than younger survivors to be obese. Also, 47 percent of survivors who received brain irradiation as part of their treatment were obese, compared to 29.4 percent of survivors who received other therapies. The risk increased for survivors whose cancer was diagnosed when they were younger than age 4 and whose treatment included glucocorticoids.
In comparison, survivors treated with chest, abdominal or pelvic irradiation were about half as likely as other survivors to be obese.
“The high prevalence of obesity in cancer survivors is of great concern and underscores the need to develop more effective counseling and weight-loss interventions for this growing population,” said first author Carmen Wilson, Ph.D., a research associate in the St. Jude Department of Epidemiology and Cancer Control.
Corresponding author Kirsten Ness, Ph.D., a member of St. Jude Epidemiology and Cancer Control, added: “Childhood cancer survivors are known to be prone to developing chronic disease. Obesity just adds to that risk.”
In the general public, obesity is associated with an increased risk of premature death as well as cancer, heart disease and other chronic health problems. St. Jude researchers are working on more effective weight management strategies for childhood cancer survivors, some possibly starting shortly after the cancer diagnosis.
The current study is one of the first to explore how genetics may impact obesity in childhood cancer survivors and the first to scan the entire genome for small variations in DNA that may influence the risk of treatment-related obesity.
Researchers identified four regions of genetic variation associated with a greater likelihood of obesity following brain irradiation, a therapy used to treat brain tumors in some patients, but no longer used to treat St. Jude patients with acute lymphoblastic leukemia (ALL). The genetic regions identified were in and around genes that have been implicated in nervous system development. The genes areFAM155A, SOX11, CDH18 and GLRA3.
“The results must be verified, but the findings suggest that variations in genes responsible for neural growth, repair and connectivity may modify the risk of obesity in childhood cancer survivors treated with cranial irradiation,” Wilson said. “Understanding the genetic basis of why certain survivors are more vulnerable to treatment-induced health problems may help us identify high-risk patients and develop strategies to reduce or better manage their risk.”
Information about diet, exercise and other lifestyle factors that influence obesity was not available for study participants.
The average survivor in this study was 32 years old and almost 25 years beyond a cancer diagnosis, making this among the most comprehensive efforts yet to understand obesity in childhood cancer survivors. The research was part of the St. Jude Lifetime Cohort Study (St. Jude LIFE), which brings cancer survivors treated at St. Jude back to the hospital for several days of health screenings and other assessments. St. Jude LIFE is the centerpiece of the hospital’s ongoing efforts to improve medical care and the quality of life for current and future childhood cancer survivors.
Treatment-related risk factors help to explain the high rate of obesity among childhood ALL survivors. In this study, 43 percent of the ALL survivors were obese, which is higher than the 19 to 32 percent reported in previous research.
The study is one of the largest yet involving survivors of pediatric solid tumors. “We found that the frequency of obesity in solid tumors survivors was higher than had been previously reported,” Wilson said. With the exception of female survivors of kidney cancer, more than 25 percent of solid tumor survivors in this study were obese.
The other study authors are Wei Liu, Jun J. Yang, Guolian Kang, Rohit Ojha, Geoffrey Neale, Deo Kumar Srivastava, James Gurney, Melissa Hudson and Leslie Robison, all of St. Jude.
The research is funded in part by a grant (CA021765) from the National Cancer Institute at the National Institutes of Health and ALSAC.
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20% to 80% since the hospital opened more than 50 years ago. St. Jude shares the discoveries it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. To learn more, visit stjude.org or follow St. Jude on social media at @stjuderesearch.